Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

LQDA vs MNKD

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
LQDA
Liquidia Corporation

Biotechnology

HealthcareNASDAQ • US
Market Cap$3.66B
5Y Perf.+356.1%
MNKD
MannKind Corporation

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.10B
5Y Perf.+135.8%

LQDA vs MNKD — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
LQDA logoLQDA
MNKD logoMNKD
IndustryBiotechnologyBiotechnology
Market Cap$3.66B$1.10B
Revenue (TTM)$69M$361M
Net Income (TTM)$-122M$-24M
Gross Margin89.4%79.3%
Operating Margin-155.0%4.1%
Forward P/E17.5x218.4x
Total Debt$122M$473M
Cash & Equiv.$176M$75M

LQDA vs MNKDLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

LQDA
MNKD
StockMay 20May 26Return
Liquidia Corporation (LQDA)100456.1+356.1%
MannKind Corporation (MNKD)100235.8+135.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: LQDA vs MNKD

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MNKD leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Liquidia Corporation is the stronger pick specifically for valuation and capital efficiency and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
LQDA
Liquidia Corporation
The Long-Run Compounder

LQDA is the clearest fit if your priority is long-term compounding.

  • 279.6% 10Y total return vs MNKD's -46.5%
  • Lower P/E (17.5x vs 218.4x)
  • +171.2% vs MNKD's -25.5%
Best for: long-term compounding
MNKD
MannKind Corporation
The Income Pick

MNKD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 0.90
  • Rev growth 22.2%, EPS growth -79.4%, 3Y rev CAGR 51.8%
  • Lower volatility, beta 0.90, current ratio 1.70x
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthMNKD logoMNKD22.2% revenue growth vs LQDA's -20.0%
ValueLQDA logoLQDALower P/E (17.5x vs 218.4x)
Quality / MarginsMNKD logoMNKD-6.6% margin vs LQDA's -176.0%
Stability / SafetyMNKD logoMNKDBeta 0.90 vs LQDA's 1.24
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)LQDA logoLQDA+171.2% vs MNKD's -25.5%
Efficiency (ROA)MNKD logoMNKD-3.9% ROA vs LQDA's -44.2%, ROIC 21.6% vs -5.0%

LQDA vs MNKD — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

LQDALiquidia Corporation
FY 2020
Promotion Agreement
100.0%$739,628
Research and Development Services
0.0%$0
MNKDMannKind Corporation
FY 2025
Product Revenue
62.0%$217M
Royalty
36.7%$128M
Service
1.2%$4M

LQDA vs MNKD — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLQDALAGGINGMNKD

Income & Cash Flow (Last 12 Months)

Evenly matched — LQDA and MNKD each lead in 3 of 6 comparable metrics.

MNKD is the larger business by revenue, generating $361M annually — 5.2x LQDA's $69M. MNKD is the more profitable business, keeping -6.6% of every revenue dollar as net income compared to LQDA's -176.0%. On growth, LQDA holds the edge at +11.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricLQDA logoLQDALiquidia Corporat…MNKD logoMNKDMannKind Corporat…
RevenueTrailing 12 months$69M$361M
EBITDAEarnings before interest/tax-$106M$25M
Net IncomeAfter-tax profit-$122M-$24M
Free Cash FlowCash after capex-$108M$13M
Gross MarginGross profit ÷ Revenue+89.4%+79.3%
Operating MarginEBIT ÷ Revenue-155.0%+4.1%
Net MarginNet income ÷ Revenue-176.0%-6.6%
FCF MarginFCF ÷ Revenue-155.8%+3.6%
Rev. Growth (YoY)Latest quarter vs prior year+11.2%+15.1%
EPS Growth (YoY)Latest quarter vs prior year+86.4%-2.2%
Evenly matched — LQDA and MNKD each lead in 3 of 6 comparable metrics.

Valuation Metrics

LQDA leads this category, winning 2 of 3 comparable metrics.
MetricLQDA logoLQDALiquidia Corporat…MNKD logoMNKDMannKind Corporat…
Market CapShares × price$3.7B$1.1B
Enterprise ValueMkt cap + debt − cash$3.6B$1.5B
Trailing P/EPrice ÷ TTM EPS-25.39x178.00x
Forward P/EPrice ÷ next-FY EPS est.17.48x218.40x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple29.32x
Price / SalesMarket cap ÷ Revenue261.40x3.15x
Price / BookPrice ÷ Book value/share42.92x
Price / FCFMarket cap ÷ FCF80.31x
LQDA leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

MNKD leads this category, winning 5 of 7 comparable metrics.

On the Piotroski fundamental quality scale (0–9), MNKD scores 4/9 vs LQDA's 1/9, reflecting mixed financial health.

MetricLQDA logoLQDALiquidia Corporat…MNKD logoMNKDMannKind Corporat…
ROE (TTM)Return on equity-5.5%
ROA (TTM)Return on assets-44.2%-3.9%
ROICReturn on invested capital-5.0%+21.6%
ROCEReturn on capital employed-84.1%+8.3%
Piotroski ScoreFundamental quality 0–914
Debt / EquityFinancial leverage1.58x
Net DebtTotal debt minus cash-$54M$399M
Cash & Equiv.Liquid assets$176M$75M
Total DebtShort + long-term debt$122M$473M
Interest CoverageEBIT ÷ Interest expense-4.63x0.75x
MNKD leads this category, winning 5 of 7 comparable metrics.

Total Returns (Dividends Reinvested)

LQDA leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in LQDA five years ago would be worth $165,255 today (with dividends reinvested), compared to $8,725 for MNKD. Over the past 12 months, LQDA leads with a +171.2% total return vs MNKD's -25.5%. The 3-year compound annual growth rate (CAGR) favors LQDA at 77.0% vs MNKD's -2.8% — a key indicator of consistent wealth creation.

MetricLQDA logoLQDALiquidia Corporat…MNKD logoMNKDMannKind Corporat…
YTD ReturnYear-to-date+34.2%-36.4%
1-Year ReturnPast 12 months+171.2%-25.5%
3-Year ReturnCumulative with dividends+454.5%-8.2%
5-Year ReturnCumulative with dividends+1552.5%-12.7%
10-Year ReturnCumulative with dividends+279.6%-46.5%
CAGR (3Y)Annualised 3-year return+77.0%-2.8%
LQDA leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LQDA and MNKD each lead in 1 of 2 comparable metrics.

MNKD is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than LQDA's 1.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LQDA currently trades 90.3% from its 52-week high vs MNKD's 54.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricLQDA logoLQDALiquidia Corporat…MNKD logoMNKDMannKind Corporat…
Beta (5Y)Sensitivity to S&P 5001.24x0.90x
52-Week HighHighest price in past year$46.67$6.51
52-Week LowLowest price in past year$11.85$2.23
% of 52W HighCurrent price vs 52-week peak+90.3%+54.7%
RSI (14)Momentum oscillator 0–10059.253.6
Avg Volume (50D)Average daily shares traded1.2M6.8M
Evenly matched — LQDA and MNKD each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates LQDA as "Buy" and MNKD as "Buy". Consensus price targets imply 96.6% upside for MNKD (target: $7) vs 20.2% for LQDA (target: $51).

MetricLQDA logoLQDALiquidia Corporat…MNKD logoMNKDMannKind Corporat…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$50.67$7.00
# AnalystsCovering analysts719
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

LQDA leads in 2 of 6 categories (Valuation Metrics, Total Returns). MNKD leads in 1 (Profitability & Efficiency). 2 tied.

Best OverallLiquidia Corporation (LQDA)Leads 2 of 6 categories
Loading custom metrics...

LQDA vs MNKD: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is LQDA or MNKD a better buy right now?

For growth investors, MannKind Corporation (MNKD) is the stronger pick with 22.

2% revenue growth year-over-year, versus -20. 0% for Liquidia Corporation (LQDA). MannKind Corporation (MNKD) offers the better valuation at 178. 0x trailing P/E (218. 4x forward), making it the more compelling value choice. Analysts rate Liquidia Corporation (LQDA) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — LQDA or MNKD?

On forward P/E, Liquidia Corporation is actually cheaper at 17.

5x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — LQDA or MNKD?

Over the past 5 years, Liquidia Corporation (LQDA) delivered a total return of +1553%, compared to -12.

7% for MannKind Corporation (MNKD). Over 10 years, the gap is even starker: LQDA returned +279. 6% versus MNKD's -46. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — LQDA or MNKD?

By beta (market sensitivity over 5 years), MannKind Corporation (MNKD) is the lower-risk stock at 0.

90β versus Liquidia Corporation's 1. 24β — meaning LQDA is approximately 38% more volatile than MNKD relative to the S&P 500.

05

Which is growing faster — LQDA or MNKD?

By revenue growth (latest reported year), MannKind Corporation (MNKD) is pulling ahead at 22.

2% versus -20. 0% for Liquidia Corporation (LQDA). On earnings-per-share growth, the picture is similar: Liquidia Corporation grew EPS -37. 2% year-over-year, compared to -79. 4% for MannKind Corporation. Over a 3-year CAGR, MNKD leads at 51. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — LQDA or MNKD?

MannKind Corporation (MNKD) is the more profitable company, earning 1.

7% net margin versus -931. 7% for Liquidia Corporation — meaning it keeps 1. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNKD leads at 11. 1% versus -866. 6% for LQDA. At the gross margin level — before operating expenses — MNKD leads at 82. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is LQDA or MNKD more undervalued right now?

On forward earnings alone, Liquidia Corporation (LQDA) trades at 17.

5x forward P/E versus 218. 4x for MannKind Corporation — 200. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MNKD: 96. 6% to $7. 00.

08

Which pays a better dividend — LQDA or MNKD?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is LQDA or MNKD better for a retirement portfolio?

For long-horizon retirement investors, MannKind Corporation (MNKD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

90)). Both have compounded well over 10 years (MNKD: -46. 5%, LQDA: +279. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between LQDA and MNKD?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LQDA is a small-cap quality compounder stock; MNKD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

LQDA

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 560%
  • Gross Margin > 53%
Run This Screen
Stocks Like

MNKD

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Gross Margin > 47%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform LQDA and MNKD on the metrics below

Revenue Growth>
%
(LQDA: 1121.7% · MNKD: 15.1%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.